Catalog No.
Product Name
Application
Product Information
Citations
-
Prostaglandin
Prostaglandin F2α 1,11-lactone primarily targets prostaglandin receptors and exhibits significant ocular absorption. This compound demonstrates metabolic stability at the corneal surface and conjunctiva, making it particularly valuable in ophthalmic research. Prostaglandin F2α 1,11-lactone is commonly employed in studies related to glaucoma treatment, providing insights into aqueous humor dynamics and intraocular pressure regulation. -
Endogenous Hormone
Prostaglandin E2 serinol amide is a non-hydrolyzable analogue of the endogenous hormone Prostaglandin E2, targeting the inhibition of the hydrolysis of [3H]2-oleoylglycerol. This compound does not convert to PGE2 and, therefore, lacks the capacity to inhibit leukotriene B4 biosynthesis, superoxide production, cellular migration, and the release of antimicrobial peptides. It serves as a useful tool for investigating the roles of prostaglandins in various biological processes. -
FP-receptor Agonist
AL-12180 is a potent and selective FP-receptor agonist, exhibiting a Ki of 143 nM. This compound effectively stimulates the mobilization of intracellular Ca2+ in human trabecular meshwork (h-TM) and cardiac muscle (h-CM) cells, demonstrating EC50 values of 111 nM and 11 nM, respectively. AL-12180 is valuable for research applications investigating FP-receptor signaling pathways and related physiological processes. -
PGF2α Analogue
Froxiprost is a PGF2α analogue that primarily targets the prostaglandin receptor pathway. It has been shown to stimulate thymidine uptake, promote the accumulation of 1,2-diacylglycerol (1,2-DAG), and facilitate the formation of phosphorylcholine in osteoblast-like MC3T3-E1 cells. This compound is valuable for research into bone metabolism, cell signaling, and the role of prostaglandins in osteogenic differentiation. -
Thromboxane Synthase Inhibitor
LG 82-4-00 is a selective thromboxane synthase inhibitor with an IC50 of 1.1 μM. This compound effectively inhibits collagen-induced formation of TXB2 and subsequently reduces platelet aggregation in plasma. LG 82-4-00 serves as a valuable tool in research focused on thrombotic disorders, contributing to the understanding of thromboxane's role in vascular biology and pathology. -
Platelet Inhibitor
Prostaglandin D3 (PGD3) is a natural prostaglandin that functions as an inhibitor of platelet aggregation. Its primary biological activity involves modulation of autonomic neurotransmission. PGD3 is utilized in research to study cardiovascular diseases and platelet activity, making it a valuable reagent for investigations into thrombosis and related conditions. -
PGF2α Analog
Prostaglandin F2α alcohol is an analog of Prostaglandin F2α (PGF2α), functioning as a potent agonist of the FP receptor. It plays a crucial role in various biological processes, including smooth muscle contraction and regulation of reproductive functions. This compound is widely utilized in research applications related to reproductive biology, inflammation, and cardiovascular studies. -
IP Receptor Agonist
19(S)-HETE is an arachidonic acid metabolite synthesized by cytochrome P450 enzymes and serves as a full orthosteric agonist of the prostacyclin (IP) receptor, exhibiting an EC50 value of 567 nM. Its biological activity includes inhibition of platelet activation and promotion of vascular relaxation. This compound is utilized in research exploring cardiovascular functions and the modulation of platelet activity. -
PGF2α Analog
17-Phenyl trinor prostaglandin F2α diethyl amide is a potent PGF2α analog known for its hypotensive effects. This compound selectively targets the prostaglandin receptor pathways, making it valuable in cardiovascular research. Its biological activity supports various studies focused on blood pressure regulation and related therapeutic applications. -
Coronary Vasodilator
Teopranitol is a coronary vasodilator that primarily targets venous dilation. This compound is essential for investigating acute myocardial ischemia, providing valuable insights into cardiac function and potential therapeutic interventions. Its selective action on venous blood vessels makes it a useful tool in cardiovascular research. -
DP2 Receptor Antagonist
AM-461 is a potent antagonist of the DP2 receptor, a key component involved in prostaglandin signaling. This compound exhibits significant potential in the study of inflammation and immunology, making it particularly relevant for research on conditions such as asthma. Its mechanism of action allows for a deeper exploration of the pathways and effects related to immune responses and inflammatory processes. -
Prostacyclin Stable Mimetic Agent
RS 93427-007 is an orally active prostacyclin stable mimetic agent that primarily targets the prostacyclin receptor. This compound exhibits significant biological activity in modulating vascular tone and inhibiting platelet aggregation, making it valuable for research in cardiovascular diseases, including atherosclerosis. RS 93427-007 serves as a critical tool for exploring therapeutic strategies aimed at vascular-related pathologies. -
TP Receptor Antagonist
TP Receptor Antagonist-2 is a selective thromboxane A2 receptor (TP receptor) antagonist, exhibiting IC50 values of 5.64 μM and 5.27 μM for the TPα and TPβ isoforms, respectively. This compound effectively inhibits platelet aggregation, making it a valuable tool for research into cardiovascular conditions and thrombotic disorders. Its application in studying TP receptor signaling pathways enhances understanding of related physiological and pathological processes. -
NSAID
Alclofenac sodium is a non-steroidal anti-inflammatory drug (NSAID) that functions as a prostaglandin H2 synthase inhibitor. It exhibits significant anti-inflammatory and analgesic properties, making it valuable in the study of rheumatoid arthritis, degenerative joint disease, and ankylosing spondylitis. This compound is instrumental for researchers investigating the underlying mechanisms and potential therapeutic strategies for inflammatory conditions. -
Prostaglandin D2 Receptor Agonist
5-trans Prostaglandin D2 is a selective agonist for the prostaglandin D2 receptor. It plays a significant role in modulating various physiological processes, including inflammation and immune responses. This compound is valuable for research applications related to allergic reactions, asthma, and neurodegenerative diseases, making it an important tool for studying prostaglandin signaling pathways. -
EP3 Receptor Antagonist
EP3 Antagonist 7 is a selective antagonist of the EP3 receptor, playing a critical role in modulating inflammatory responses. This compound exhibits significant biological activity in the context of pain, pruritus, dysuria, and various stress-related disorders. Its application in research provides insight into the physiological mechanisms and therapeutic targets associated with EP3 receptor signaling. -
Prostanoid Receptor Ligand
11-epi-PGE1 (11β-Prostaglandin E1) is a prostanoid receptor ligand that serves as a less potent isomer of Prostaglandin E1. This compound is utilized in research to investigate the modulation of prostanoid signaling pathways and their associated biological effects. Its unique properties may facilitate studies in inflammation, vascular biology, and other physiological processes where prostaglandins play a crucial role. -
TXA2 Receptor Antagonist
Z-335 sodium is an orally active thromboxane A2 (TXA2) receptor antagonist. It demonstrates potent inhibition with IC50 values of 29.9 nM and 32.5 nM in human and guinea pig platelets, respectively. This compound is useful in studying the physiological and pathological roles of TXA2 in various conditions, including cardiovascular diseases and platelet aggregation. -
EP3 receptor Antagonist
EP3 antagonist 5 is a selective antagonist of the EP3 receptor, exhibiting an IC50 value of 67 nM. This compound effectively inhibits EP3 receptor-mediated signaling, making it a valuable tool for studying the role of prostaglandin E receptors in various biological processes. Its application spans research into inflammatory responses, pain mechanisms, and potential therapeutic strategies for related diseases. -
TPα/β Antagonist
TPα/β antagonist-1 is a selective antagonist of the thromboxane A2 receptors TPα and TPβ, exhibiting IC50 values of 1.52 nM and 0.79 nM, respectively. This compound effectively inhibits U-46619-induced intracellular calcium mobilization and reduces platelet aggregation. TPα/β antagonist-1 is valuable for investigating mechanisms underlying cardiovascular diseases and evaluating potential therapeutic strategies. -
PGA2 Analog
15-Deoxy-Δ12,14-prostaglandin A2 is a synthetic analog of prostaglandin A2 (PGA2) that primarily acts through the modulation of inflammatory responses. This compound exhibits significant biological activity by influencing various signaling pathways related to cell proliferation and apoptosis. It is commonly utilized in research applications focused on investigating the role of prostaglandins in inflammation, cardiovascular health, and tumor biology. -
Urinary Metabolite
PGDM (Prostaglandin D Metabolite) is the principal urinary metabolite of Prostaglandin D2, exhibiting reversible cyclization. This compound holds potential as a biomarker for the endogenous synthesis of PGD2 and is valuable in assessing the severity of acute allergic reactions. Its role in studying allergic responses makes PGDM significant for research in immunology and inflammation. -
Cervical Dilator
Meteneprost is a cervical dilator that enhances uterine contractility and facilitates the dilation of the cervical canal. This compound is utilized primarily in obstetric and gynecological research applications, particularly for inducing labor or preparing the cervix for medical procedures. Its ability to promote cervical changes makes it a valuable tool in studies focused on reproductive health and therapeutic interventions. -
Thromboxane Antagonist
L 640035 is a thromboxane antagonist that selectively inhibits the action of thromboxane A2, a potent vasoconstrictor and platelet aggregator. This compound demonstrates significant biological activity in modulating platelet aggregation and vascular tone, making it valuable for research in cardiovascular disorders and thrombotic diseases. It serves as a useful tool for studying the role of thromboxane in pathophysiological conditions and evaluating potential therapeutic interventions. -
Prostaglandin D Synthase Inhibitor
Pizuglanstat hydrate is a potent inhibitor of prostaglandin D synthase, exhibiting an IC50 of 76 nM for human hematopoietic prostaglandin D synthase. This compound effectively inhibits the synthesis of prostaglandin D2, making it relevant in research into inflammatory conditions. Pizuglanstat hydrate has demonstrated efficacy in improving experimental allergic rhinitis and offers potential applications in the study of muscle regenerative diseases, including muscular dystrophy. -
Prostaglandin Analog
17-trans Prostaglandin E3 is a prostaglandin analog that activates Nurr1-dependent transcriptional activity. This compound is instrumental in investigating biological processes related to Nurr1, including its implications in cancer and autoimmune diseases. Its properties make it valuable for research focused on these conditions and the underlying mechanisms of Nurr1 signaling. -
CRTH2 Antagonist
TASP0376377 is a highly potent and selective antagonist of the CRTH2 receptor, exhibiting an IC50 of 13 nM. This compound demonstrates strong binding affinity for CRTH2, with an IC50 of 19 nM. TASP0376377 is valuable for research applications focusing on inflammatory responses and immune modulation, particularly in studies related to asthma, allergy, and other CRTH2-related pathways. -
PGF2 Analog
15(R)-15-Methyl Prostaglandin F2α is a metabolically stable analog of PGF2α targeting prostaglandin receptors. This pharmacologically inactive prodrug is designed for activation through gastric acid, where acid-catalyzed epimerization converts it into the active 15(S)-isomer. The 15(S)-isomer effectively induces luteolysis in rhesus monkeys at approximately 12 mg per animal, making this compound valuable for research in reproductive biology and prostaglandin signaling pathways. -
Thromboxane A2 Receptor Antagonist
Vapiprost hydrochloride is a thromboxane A2 receptor antagonist that effectively inhibits platelet aggregation and ATP release induced by U-46619, collagen, or arachidonic acid (AA), with an IC50 of less than 2.1 × 10^-8 M. This compound serves as a valuable tool in studies focused on thromboxane signaling pathways and their implications in cardiovascular research. Its ability to modulate platelet activity makes it useful for investigating the mechanisms underlying thrombotic disorders and developing therapeutic interventions. -
TXA2/PGH2 Receptor Antagonist
LCB 2853 sodium is a potent antagonist of the thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptor, demonstrating significant anti-aggregant and anti-vasospastic properties. This compound is useful for investigating cardiovascular diseases, including hypertension, by providing insights into the modulation of platelet aggregation and vascular response. Its role in cardiovascular research highlights its potential as a valuable tool in the study of related pathophysiological processes. -
Antithrombotic Agent
15(R)-PTA2, also known as 15(R)-Pinanethromboxane A2, functions as an antithrombotic agent primarily by inhibiting platelet aggregation. This compound effectively counteracts the constriction induced by stable prostaglandin endoperoxide analogs in feline coronary arteries while also stabilizing hepatic lysosomes. Additionally, 15(R)-PTA2 inhibits thromboxane synthase without affecting prostacyclin synthase, making it a valuable tool in cardiovascular research and the study of thrombotic disorders. -
PG analog
20-Ethyl prostaglandin E2 is a prostaglandin analog that primarily targets Nurr1, activating its transcriptional activity. This compound is useful in studies examining the regulation of gene expression and the role of Nurr1 in various biological processes, including neuroprotection and inflammation. Its application in research can provide insights into potential therapeutic strategies for conditions related to these pathways. -
Prostaglandin E Analogue
Flunoprost is a stabilized analogue of prostaglandin E, primarily targeting prostaglandin receptors. It exhibits significant biological activities, including the modulation of inflammatory responses and vascular function. Flunoprost is widely utilized in research applications related to cardiovascular studies, reproductive biology, and the exploration of inflammatory mediators. -
Prostaglandin I1 Analogue
Pimilprost is a prostaglandin I1 analogue that primarily targets the prostaglandin pathway. It exhibits significant antithrombotic activity and enhances intracellular cAMP levels. Pimilprost has demonstrated potential in promoting wound healing by stimulating angiogenesis and improving blood flow in diabetic models. This compound is valuable for research investigating metabolic and cardiovascular diseases, particularly in the context of diabetes. -
Isomer
5,6-trans-Travoprost is an isomer of Travoprost, serving as a critical experimental control in research. This compound acts as a selective, high-affinity agonist for the FP prostaglandin receptor, demonstrating significant ocular hypotensive effects. Primarily, 5,6-trans-Travoprost is utilized in studies related to glaucoma and ocular hypertension, facilitating investigations into therapeutic interventions for these conditions. -
IOP Lowering Agent
Prostaglandin F2α methyl ester is a lipophilic analog of Prostaglandin F2α, primarily functioning as an intraocular pressure (IOP) lowering agent. This compound effectively promotes aqueous humor outflow, leading to reduced intraocular pressure, which is critical in the management of glaucoma. Its unique solubility properties enhance its utility in ocular formulations and research applications related to eye health and disease. -
EP3 Receptor Antagonist
EP3 antagonist 6 is a selective EP3 receptor antagonist that demonstrates a potent inhibitory effect with an IC50 of 1.9 nM. This compound effectively blocks PGE2-induced uterine contractions in pregnant rat models, making it a valuable tool for exploring reproductive physiology and therapeutic interventions in uterine contractility. Its application in research can help elucidate the role of EP3 receptors in various biological processes. -
Prostaglandin Analog
15(R)-17-Phenyl trinor Prostaglandin F2α is a prostaglandin F (FP) analog that primarily targets FP receptors. It serves as an ocular hypotensive agent, although its structural modification results in reduced agonist activity at FP receptors compared to its active free acid counterpart, 17-Phenyl trinor Prostaglandin F2α. This compound is relevant in research applications focusing on glaucoma treatment and prostaglandin signaling pathways. -
TXA2R Antagonist
ICI 192605 is a potent antagonist of the thromboxane A2 receptor (TXA2R), a key regulator in cell signaling pathways involving prostaglandins. This compound effectively inhibits the contraction of isolated guinea pig trachea triggered by U-46619, demonstrating its potential in respiratory research. ICI 192605 is valuable for studies investigating the role of TXA2R in various physiological and pathological processes. -
Prostaglandin FP Receptor Agonist
Tafluprost ethyl ester is an agonist of the prostaglandin FP receptor, derived from Prostaglandin F2α (PGF2α). This compound demonstrates a myotic effect, making it useful in research related to ocular pressure reduction and glaucoma treatment. Its activity as a prostaglandin receptor modulator allows for exploration in various biological and pharmacological studies focused on intraocular effects and other prostaglandin-related pathways. -
Travoprost Derivate
13,14-epoxy Travoprost is a derivative of Travoprost, functioning primarily as a selective agonist for the prostaglandin F receptor. This compound exhibits significant ocular hypotensive activity, making it relevant for research into treatments for glaucoma and other intraocular pressure-related conditions. Its diastereomeric epoxide mixture provides a unique avenue for studying the pharmacological effects and mechanisms of action associated with prostaglandin analogs in ocular therapeutics. -
Prostaglandin Receptor Inhibitor
RS-61756-007 is a selective thromboxane receptor (TP) agonist that exhibits high affinity and activity specifically at the TP receptor. In vitro studies demonstrate that RS-61756-007 also shows agonistic effects at FP receptors, while remaining inactive against other receptor subtypes. The biological effects of RS-61756-007 can be effectively inhibited by the TP antagonist SQ 29,548. This compound is valuable for research aimed at understanding thromboxane signaling and its implications in various physiological and pathological processes. -
CRTH2 Antagonist
AM432 sodium is a selective antagonist of the CRTH2 receptor, also known as DP2. This compound exhibits high potency in human whole blood eosinophil assays, particularly under prolonged incubation conditions. Additionally, AM432 sodium has shown favorable pharmacokinetic profiles in canine and murine models of inflammatory diseases, making it a valuable tool for research in immunology and inflammatory pathways. -
Thromboxane Synthetase Inhibitor
Y-20811 sodium is a selective thromboxane synthetase inhibitor that exhibits potent and irreversible inhibition of thromboxane A2 synthesis. This compound is primarily utilized in cardiovascular research, particularly in studying thrombosis and its associated pathophysiological mechanisms. Its oral bioactivity makes it a valuable tool for investigating therapeutic interventions in thromboxane-related vascular disorders. -
PGF2α Analogues
17-Phenyl trinor prostaglandin F2α methyl amide is a potent analog of prostaglandin F2α (PGF2α) that selectively competes with native PGF2α for receptor binding. This compound exhibits key biological activities that enable its use in studies focused on reproductive biology and cardiovascular physiology. It serves as a valuable tool for investigating PGF2α-mediated signaling pathways and related therapeutic applications. -
Antithrombotic Agent
NP-184 is an innovative orally active antithrombotic agent that selectively inhibits thromboxane A2 (TXA2) synthase, demonstrating an IC50 of 4.3 μM. This compound exhibits notable antiplatelet and antithrombotic properties, making it valuable for research in thromboembolic diseases. Its targeted mechanism of action positions NP-184 as a significant tool in the study of cardiovascular disorders and related therapeutic developments. -
EP2 Agonist
(S)-Butaprost free acid is a potent and selective agonist of the EP2 receptor. This compound modulates various biological processes, including inflammation and smooth muscle relaxation. It is effectively utilized in research related to cardiovascular and respiratory diseases, as well as studies focused on reproductive biology. -
Prostacyclin Analogue
Naxaprostene is a selective prostacyclin analogue that primarily targets IP receptors, exhibiting partial agonistic activity. This compound effectively inhibits ADP-induced platelet aggregation, demonstrating significant antithrombotic properties. Naxaprostene has been shown to prevent thrombosis in models such as rabbit carotid artery, making it a valuable tool in cardiovascular research and studies focusing on platelet function and vascular health. -
Spasmodic
8-iso Prostaglandin E1 is a spasmodic agent that primarily targets pulmonary vascular smooth muscle. It exhibits significant vasodilatory properties, particularly in canine pulmonary veins, making it valuable for studies related to pulmonary hypertension and vascular dysfunction. This compound is useful in research focusing on the regulation of vascular tone and respiratory physiology. -
Prostacyclin Analogue
Ciprostene calcium is a prostacyclin analogue that primarily targets platelet activation pathways. It effectively inhibits adenosine diphosphate-induced platelet aggregation, making it a valuable tool in studies related to thromboembolic disorders. This compound is particularly useful in researching peripheral vascular disease and related cardiovascular conditions.
